Vaxiion Therapeutics, Inc. v. Foley & Lardner LLP

ORDER: (1) DENYING PLAINTIFF’S MOTION FOR SUMMARY ADJUDICATION OF LIABILITY [Doc. No. 94]; (2) GRANTING DEFENDANT’S MOTION TO STRIKE EVIDENCE CITED IN SUPPORT OF PLAINTIFF’S MOTION [Doc. No. 131]; (3) DENYING AS MOOT DEFENDANT’S MOTION TO STRIKE EVIDENCE OF SETTLEMENT MEETING CITED IN SUPPORT OF PLAINTIFF’S REPLY [Doc. No. 146] IRMAE. GONZALEZ, Chief Judge. Plaintiff Vaxiion Therapeutics (“Vaxiion”) moves the Court for summary adjudication of liability on its Negligence and Breach of Fiduciary Duty Claims. Defendant Foley & Lardner (“Foley”) has filed an opposition. Defendant has also filed a motion to strike evidence cited in support of plaintiffs motion for summary adjudication and a motion to strike evidence of a settlement meeting cited in support of plaintiffs reply in support of motion for summary adjudication. The Court heard oral argument on the motions on November 10, 2008. After considering all the arguments of the parties, for the reasons explained herein, the Court DENIES plaintiffs motion for summary adjudication and GRANTS defendant’s motion to strike evidence cited in support of plaintiffs motion. The Court also DENIES AS MOOT defendant’s motion to strike evidence of settlement meeting, and overrules all of the parties’ evidentiary objections except those the Court specifically addresses herein. BACKGROUND Vaxiion 1 is a startup biotechnology research company that first began performing minicell 2 research in August of 1999. [Transcript of February 20, 2008 Deposition of Roger Sabbadini (“Sabbadini Depo. G”), Ex. G to Garner Decl. ISO Opp. to Motion (“Garner Decl.”), Doc. No. 116-13, p. 53:21.] Attorney Richard Warburg performed patent work for Vaxiion in the late 1990s when he worked at the firm of Lyon *1157 & Lyon. (Motion at 2.) In 1999, Warburg went to Brobeck, Phelger & Harrison LLP and took Vaxiion with him as a client. [Transcript of February 20, 2008 Deposition of Roger Sabbadini (“Sabbadini Depo. A”), Ex. A to Motion, Doc. No. 94-2, pp. 173:1-24.] There, Warburg began working with an associate, Andrew Granston, on the drafting and prosecution of patent applications for Vaxiion. Both Granston and Warburg began practicing law at Foley and Lardner in early 2001 [Warburg Decl. ISO Opp. to Motion (“Warburg Deck”), Doc. No. 116-49, ¶ 1; Granston Deck ISO Opp. to Motion (“Granston Deck”), Doc. No. 116-23, ¶ 1,] and Vaxiion continued to retain them as counsel in part to continue work on the minicell patent application. (Granston Deck at ¶¶ 4-5.) Roger Sabbadini, Vaxiion’s founder, felt comfortable with Warburg and Granston’s qualifications and competence when he asked them to draft Vaxiion’s first minicell application. (Granston Decl. at ¶¶ 3-5; Sabbadini Depo. G, pp. 181:21-182:23.) On May 24, 2001, Warburg 3 and Granston filed a U.S. provisional patent application on behalf of Vaxiion entitled “Minicell Compositions and Methods” (“First Provisional Application”). (Complaint, ¶¶ 6-7; Granston Decl. at ¶ 6, Ex. B.) Both Foley and Vaxiion worked together to prepare the First Provisional Application. [Granston Deck at ¶¶ 6, 10; Transcript of February 8, 2008 Deposition of Neil Berkley (“Berkley Depo.”), Ex. K to Garner Decl., Doc. No. 116-18, pp. 50:6-51:5, 56:14-22, 63:12-20; Sabbadini Depo. G, pp. 185:19— 25.] On February 25, 2002, Foley attorneys Warburg and Granston filed a second provisional application with the same title (“Second Provision Application”). (Complaint, ¶¶ 6-7; Granston Deck at ¶ 9, Ex. E.) Vaxiion was fully satisfied with both the First and Second Provisional Applications. [Transcript of July 8, 2008 Deposition of Harry F. Manbeck, Jr. (“Manbeck Depo.”), Ex. F. to Garner Decl., Doc. No. 116-12, pp. 225:20-23; Sabbadini Depo. G, pp. 186:19-21, 203:14-16; Granston Decl. at ¶¶ 6, 9, Exs. C, F.] To claim priority in the U.S. to the First Provisional Application filed on May 24, 2001, Vaxiion had to file a non-provisional (or “utility”) U.S. application within one year, or by May 24, 2002. In order to claim priority to the First Provisional Application outside the U.S., Vaxiion had to file a Patent Cooperation Treaty (“PCT”) application by the same date. In July 2001, Vaxiion hired Mark Surber as its Chief Scientific Officer. Surber became the primary contact with Foley regarding the utility and PCT applications. [Granston Decl. at ¶ 16; Transcript of February 15, 2008 Deposition of Mark Surber, Ph.D. (“Surber Depo.”), Ex. J. to Garner Decl., Doc. No. 116-17, pp. 55:21-56:1; 61:11-13; Sabbadini Depo. G., pp. 202:22-25, 223:5-225:16.] Over the course of many months, Foley and Vaxiion prepared the patent applications. (Granston Decl. at ¶¶ 10-22, Exs. G, I-L, O-T; Warburg Decl. at ¶¶ 15-23, Ex. A; Surber Depo., pp. 69:3-71:5; Sabbadini Depo. G, pp. 224:4-223:7.) War-burg and Granston advised Sabbadini, Surber, and William Gerhart, Vaxiion’s Chief Executive Officer, that -it would be best to file separate United States Non-Provisional and PCT applications as opposed to a single PCT application (although in the end the two applications were not substantively different). As such, the Foley lawyers and their clients made the decision together to file the separate applications. *1158 (Surber Depo., pp. 69:10-71:7; Sabbadini Depo. G, pp. 221:7-223:3; Granston Decl. at ¶¶ 11-15; Warburg Decl. at ¶¶ 15-20.) 4 Furthermore, as part of their filing strategy, the parties agreed to file twenty-three individual patent applications with discrete proposed sets of claims (“non-provisional divisional applications”), as opposed to one application including all 464 of Vaxiion’s claims. (Surber Depo., pp. 69:10-71:7; Sabbadini Depo. G, pp. 221:7-223:3; Granston Decl. at ¶¶ 11-14; Warburg Decl. at ¶¶ 15-20.) Vaxiion decided to rely on Granston rather than Warburg for the actual drafting of the minicell patent applications (because of Granston’s lower billing rate), and communicated primarily with Granston throughout the process. (Sabbadini Depo. G, pp. 181:21-184:23, 200:25-201:11; Warburg Decl. at ¶¶ 8-11, 13, Exs. A-M; Granston Decl. at ¶ 8, 10, Exs. G-N.) Vaxiion was aware of the amount of time Granston spent preparing the United States First and Second Provisional Applications, the U.S. Non-Provisional Application and PCT Application, as compared to the time Warburg spent on the same. (Warburg Decl. at ¶¶ 8-10, Exs. A-F; Granston Decl. at 110, Exs. G-L; Sabbadini Depo. G, pp. 181:21-184:23, 200:25-201:11.) In the month leading up to the filing deadline, the limited time left to file the multiple divisional applications concerned Surber because he felt Granston did not incorporate his suggestions into the applications quickly enough (Transcript of February 15, 2008 Deposition of Mark Surber, Ph.D., Ex. B to Reply, Doc. No. 140-3, pp. 96-97.) Foley claims that during the same time period Warburg continually warned Vaxiion how important it was for Vaxiion to get the information Foley needed to file the divisional applications by the deadline. (Warburg Decl. at ¶ 21-22.) Notwithstanding these concerns on both sides, Sabbadini reviewed the specification and claims Warburg and Granston assembled on May 23, 2002 at 6:06 p.m. (the evening before the deadline), proposed no changes to the claims, and believed the application was “excellent” and ready to be filed at that time. (Sabbadini Depo. G, pp. 238:24-239:89-12.) The parties do not dispute Foley knew the PCT application had a May 24, 2002 filing deadline, [Sabbadini Depo. G, pp. 208:20-209:6; Surber Depo., pp. 61:14-24; Ex. H to Motion (November 20, 2002 Letter from Sandra A’Costa to Bill Gerhart [Vaxiion’s CEO] reminding him of [the] May 24, 2002 deadline), Doc. No. 94-9; Ex. I to Motion (April 24, 2002 Letter from A’Costa to Gerhart reminding him of the May 24, 2002 deadline), Doc. No. 94-10] that the United States post office closed on 11:00 p.m. on the night of May 24, 2002, and that Granston explained to Surber that he had to deliver the applications to the post office by 11:00 p.m. to receive a May 24 postmark on the application. (Granston Decl. at ¶ 24.) Surber nevertheless continued to provide Granston with changes, comments, and additions up until the evening hours before the filing deadline of 11:00 p.m. on May 24, 2002. [Granston Decl. at ¶¶ 22-28, Exs. V-X; Surber Depo., pp. 87:14-89:2, Ex. 99 (timeline of events of May 24, 2002 prepared by Surber).] Granston unilaterally abandoned the strategy of filing the multiple divisional applications in favor of filing one United States non-provisional application on May 24, 2002, as the filing *1159 deadline “got closer and Surber still had not given his approval to file.” (Opp. at 12, n. 13; see also Reply at 8.) The last of Surber’s series of changes came at 9:50 p.m. on the night of the deadline when Surber instructed Granston by telephone to add several hundred pages of DNA sequences to the application. (Granston Decl. at ¶ 28, Ex. V; Decl. of Christine E. Whitten, M.D. ISO Opp. (“Whitten Decl.”), at ¶¶ 5-6; Decl. of Michelle Sympson ISO Opp. (“Sympson Decl.”), at ¶¶ 7-8.) Granston explained to Surber that the changes were unnecessary, they could be added later by amendment, and that if Granston tried to include them he could not guarantee the filing deadline could be met. (Granston Decl. at ¶ 28.) Surber insisted they be added anyway. (Id.) Surber emailed the sequences to Granston at 10:01 p.m., and due to their size, Granston did not receive them all until 10:09 p.m. (Granston Decl. at ¶ 28, Ex. V; Surber Depo., pp. 87:14-89:2, Ex. 99.) At 10:20 p.m., Granston finalized the application, including the DNA sequences, emailed the U.S. Non-Provisional Application to his assistant Michelle Sympson to finalize, and emailed the PCT application to paralegal Sandra A’Costa to format to conform to the PCT formatting rules. (Granston Decl. at ¶ 29, Ex. V; Surber Depo, pp. 87:14-89:2, 184:2-9, 225:5-15; Sympson Decl. at ¶ 9-11.) Dr. Christine Whitten, Granston’s girlfriend at the time (now his wife) was also at Foley’s offices that night in order to drive with Granston to the post office but did not participate in the preparation or filing of any of Vaxiion’s patent applications. (Granston Decl. at ¶ 30; Whitten Decl. at ¶¶ 2-3.) At approximately 10:40 p.m., Granston left for the post office with the completed Non-Provisional Application, and asked Whitten to stay behind until the PCT Application was completed, to drive it to the post office. (Whitten Decl. at ¶ 7.) At that time, Whit-ten states, A’Costa was having trouble formatting the PCT because her computer kept freezing. Once the computer was working, A’Costa formatted the application, but by the time she finished it was past 11:00 p.m., and the post office had closed. (Whitten Decl. at ¶ 8; Sympson Decl. at ¶ 13.) Despite trying to reach contacts in Alaska and Hawaii who could still potentially obtain a May 24 postmark on the PCT Application because of the time zone difference, Granston was unable to file the application by the deadline. (Whitten Decl. at ¶ 10-11; Sympson Decl. at ¶ 15.) Vaxiion thus successfully filed a non-provisional U.S. patent application (“Non-Provisional Application”) on May 24, 2002, claiming priority to the First and Second Provisional Applications, (Granston Decl. at ¶ 30, Ex. Y,) and filed the PCT application the next business day, May 28, 2002. (Warburg Decl. affl 25.) As a result of the missed PCT Application deadline, Vaxiion is not able to claim priority internationally to the May 24, 2001 First Provisional Application, but only to the February 25, 2002 Second Provisional Application. After Foley filed the First Provisional Application on Vaxiion’s behalf on May 24, 2001, but before Foley filed the Second Provisional Application on Vaxiion’s behalf on February 25, 2002, an attorney in Foley’s Washington D.C. office, Stephen Bent, filed a provisional application for an Australian company, EnGeneIC, also covering certain aspects of minicell technology. [Bent Decl. ISO Opp. (“Bent Deck”), Doc. No. 116-2 at ¶ 2.] On October 15, 2001, Bent filed on behalf of EnGeneIC a provisional application, titled “Intact Mini-cells as Vectors for DNA Transfer and Gene Therapy In Vitro and In Vivo.” (Id.) EnGenelC’s PCT Application, which was filed one year later on October 15, 2002, claims priority to EnGenelC’s provisional *1160 application, and as a result is considered senior to Vaxiion’s PCT Application. (Id. at ¶ 4.) Foley represented both Vaxiion and EnGeneIC from November 2001 until June 2002. Prior to the publication of EnGenelC’s PCT Application on April 24, 2003, neither Warburg nor Granston knew of EnGenelC’s provisional application or that Foley D.C. attorney Bent represented EnGeneIC. (Warburg Decl. at ¶27; Granston Decl. at ¶ 33.) In July 2002, (War-burg Decl. at ¶ 26,) Vaxiion terminated its relationship with Foley and instead retained the services of the law firm of Knobbe Martens Olson & Bear. Knobbe Martens continued its prosecution of Vaxiion’s patent applications for minicell technology. On February 27, 2007, the USP-TO issued to Vaxiion Patent No. 7,183,105 (the “105 Patent”), which claimed priority to the First and Second Provisional Applications. (Garner Decl. at ¶ 4, Ex. D.) Vaxiion learned that Foley represented EnGeneIC no later than November 2004. (Sabbadini Depo. G, p. 251.) Vaxiion never, however, raised an issue regarding Foley’s continued representation of EnGeneIC until late August 2007, when Plaintiffs counsel indicated Vaxiion would not produce certain laboratory notebooks in discovery because of Foley’s continued representation of EnGeneIC. (Garner Decl. at ¶ 17.) Foley withdrew from its representation of EnGeneIC with respect to EnGenelC’s PCT Application and EnGenelC’s Non-Provisional U.S. Application, in late 2007 or early 2008. (Bent Decl. at ¶ 7.) Foley continues to represent EnGeneIC in some patent matters. Before Foley withdrew from its representation of EnGeneIC, in 2006 and 2007, a PTO examiner rejected several claims in EnGenelC’s Non-Provisional U.S. Application partly in light of Vaxiion’s Non-Provisional U.S. Application. (McCaslin Decl. at ¶¶2 and 4, Exs. A and C.) In response to the examiner’s rejection, Foley on behalf of EnGeneIC submitted declarations attempting to antedate the Vaxiion prior art reference (i.e. demonstrate EnGeneIC reduced its invention to practice before Vaxiion). (McCaslin Decl. at ¶¶ 3 and 5.) On July 25, 2007, the PTO withdrew its rejection of EnGenelC’s Non-Provisional Application based upon Vaxiion’s Non-Provisional U.S. Application, and instead rejected EnGenelC’s application based upon Vaxiion’s then-issued '105 Patent. (Id. at ¶ 6, Ex. E.) DISCUSSION A. Legal Standard Summary judgment is proper where the pleadings and materials demonstrate “there is no genuine issue as to any material fact and ... the moving party is entitled to judgment as a matter of law.” Fed.R.Civ.P. 56(c); Celotex Corp. v. Catrett, 477 U.S. 317, 322, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). A material issue of fact is a question the trier of fact must answer to determine the rights of the parties under the applicable substantive law. Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986). A dispute is genuine “if the evidence is such that a reasonable jury could return a verdict for the nonmoving party.” Id. at 248, 106 S.Ct. 2505. The moving party bears “the initial responsibility of informing the district court of the basis for its motion.” Celotex, 477 U.S. at 323, 106 S.Ct. 2548. To satisfy this burden, the moving party must demonstrate that no genuine issue of material fact exists for trial, Id. at 322, 106 S.Ct. 2548, and may do this by “pointing out to the district court that there is an absence of evidence to support the nonmoving party’s case.” Celotex, 477 U.S. at 325, 106 *1161 S.Ct. 2548: see Nissan Fire & Marine Ins. Co. v. Fritz Cos., 210 F.3d 1099, 1106 (9th Cir.2000). Additionally, to obtain a summary judgment, “ ‘the moving party must offer evidence sufficient to support a finding upon every element of his [or her] claim ..., except those elements admitted ... ’ by the adversary.” Watts v. United States, 703 F.2d 346, 347 (9th Cir.1983) (citing United States v. Dibble, 429 F.2d 598, 601 (9th Cir.1970)). However, the moving party is not required to negate those portions of the non-moving party’s claim on which the non-moving party bears the burden of proof. Celotex, 477 U.S. at 323, 106 S.Ct. 2548. To withstand a motion for summary judgment, the non-movant must then show that there are genuine factual issues which can only be resolved by the trier of fact. Reese v. Jefferson Sch. Dist. No. 14J, 208 F.3d 736, 738 (9th Cir.2000) (citing Fed.R.Civ.P. 56; Celotex, 477 U.S. at 323, 106 S.Ct. 2548). The nonmoving party may not rely on the pleadings but must present specific facts creating a genuine issue of material fact. Nissan Fire, 210 F.3d at 1103. The inferences to be drawn from the facts must be viewed in a light most favorable to the party opposing the motion, but conclusory allegations as to ultimate facts are not adequate to defeat summary judgment. Gibson v. County of Washoe, Nev., 290 F.3d 1175, 1180 (9th Cir.2002). The Court is not required “to scour the record in search of a genuine issue of triable fact,” Keenan v. Allan, 91 F.3d 1275, 1279 (9th Cir.1996), but rather “may limit its review to the documents submitted for purposes of summary judgment and those parts of the record specifically referenced therein.” Carmen v. San Francisco Unified Sch. Dist., 237 F.3d 1026, 1030 (9th Cir.2001). B. Motions to Strike and Evidentiary Objections Defendant has brought two motions to strike evidence which plaintiff cites in support of its Motion: (1) Motion to Strike Evidence Cited In Plaintiffs Motion for Summary Adjudication (“Motion to Strike MSA Evidence,” Doc. No. 131); (2) Motion to Strike Evidence of Settlement Meeting Cited in Support of Plaintiffs Reply in Support of Motion for Summary Adjudication (Doc. No. 146.) Both parties also filed numerous evidentiary objections. As explained below, the Court GRANTS defendant’s Motion to Strike MSA Evidence because plaintiff has not shown that its expert is qualified to give opinions with regard to legal ethics and conflicts of interest. 5 The Court finds defendant’s second motion to strike and the parties’ evidentiary objections beyond those discussed below do not impact the Court’s substantive determination of the merits of plaintiffs motion for summary adjudication. The Court accordingly DENIES the motion and objections as moot. Defendant objects to the following deposition testimony excerpts and opinions rendered in the expert reports 6 of plaintiffs expert Harry F. Manbeck: *1162 1. Transcript of July 8, 2008 Deposition of Harry F. Manbeck, Jr., page 65, line 20 through page 66, line 18, regarding a legal ethics rule at issue in this case, [ (“Manbeck Depo.”), Doc. No. 131-44, Ex. A to Motion to Strike MSA Evidence, pp. 65:20-66:18] PTO Code Section 10.66. 37 C.F.R. § 10.66. (Memo. ISO Motion to Strike MSA Evidence at 2.) Plaintiff cites the testimony in its Motion and Separate Statement in Support of Motion for Summary Adjudication [ (“Separate Statement”), Doc. No. 94-47] to support its argument that Foley breached its fiduciary duty to Vaxiion. 2. Any paragraphs of Manbeck’s expert reports discussing his opinions on ethics and conflicts of interest, “to the extent that plaintiff intends to rely upon them.” (Memo. ISO Motion to Strike MSA Evidence at 3 n. 2.) 3. Paragraphs 41, 43, 44, and 48 of the Expert Report of Harry Manbeck cited in plaintiffs Separate Statement, paragraphs 7 and 22. [Defendant’s Objections to Plaintiffs Evidence ISO Motion for Summary Adjudication (“Evid. Objections”), Doc. No. 117, at 2-6.] Plaintiff cites the report in support of its assertion Foley committed professional negligence in its untimely filing of the PCT application. 4. Paragraph 5 of the Rebuttal Expert Report of Harry Manbeck cited in plaintiffs Separate Statement, paragraph 9 (Evid. Objections at 6.) Plaintiff cites the rebuttal report in support of its assertion Foley committed professional negligence in its untimely filing of the PCT application. 5.Transcript of July 8, 2008 Deposition of Harry F. Manbeck, Jr., page 187, line 3 through line 23, and page 189, line 23 though page 190, line 23, cited in plaintiffs Separate Statement, paragraph 9. (Evid. Objections at 7, 9.) Plaintiff cites the testimony in support of its assertion Foley committed professional negligence in its untimely filing of the PCT application. Defendant argues this evidence is inadmissible under Fed.R.Evid. 702 because Man-beck does not have the knowledge, skill, experience, training or education in the area of attorney ethics or attorney standards of care to enable him to render expert opinions in these areas, even though Manbeck may be qualified to opine on matters relating to patent procedures. See, e.g. Memo. ISO Motion to Strike MSA Evidence at 3. Essentially, defendant argues Manbeck is no more qualified than the average lawyer to testify about legal ethics or conflicts of interest. Federal Rule of Evidence 702 provides, in relevant part: If scientific, technical, or other specialized knowledge will assist the trier of fact to understand the evidence or to determine a fact in issue, a witness qualified as an expert by knowledge, skill, experience, training, or education, may testify thereto in the form of an opinion or otherwise .... Fed.R.Evid. 702 (2008). To qualify as an expert, a witness must have “knowledge, skill, experience, training, or education” relevant to such evidence or fact in issue, Id., and “expert testimony must ... address an issue beyond the common knowledge of the average layman.” United States v. Vallejo, 237 F.3d 1008, 1019 (9th *1163 Cir.2001), amended by 246 F.3d 1150 (9th Cir.2001). The admissibility of expert testimony is within the sound discretion of the trial judge, “who alone must decide the qualifications of the expert on a given subject and the extent to which his opinions may be required.” United States v. Chang, 207 F.3d 1169, 1172 (9th Cir.2000) (citation omitted). Plaintiff designated Manbeck 7 as its sole expert not only on patent procedure matters, but also on legal ethics and conflict of interest matters. [Export Report of Harry F. Manbeck, Jr. (“Man-beck Report”), Doc. No. 94-31, Ex. “V” ISO Motion at ¶ 5.] Manbeck testified in his deposition that he has never held himself out as an expert on legal ethics, patent ethics, or conflicts of interest. [Transcript of July 8, 2008 Deposition of Harry Manbeck (“Manbeck Depo. A”), Ex. A to Garner Deck ISO Motion to Strike MSA Evidence, Doc. No. 131-3, pp. 36:9-14.] Manbeck also testified he: (1) never received any training on ethics issues (Id., p. 34, lines 11-15); (2) never represented a party in a legal malpractice case (Id., p. 80, lines 18-22); (3) has only been designated an expert in (at most) two legal malpractice cases, neither having to do with conflicts of interest (Id., p. 35, line 2-36, line 25); and (4) as USPTO Commissioner was not involved in disciplining lawyers and did not oversee the revisions of any ethics rules (Id., pp. 25, line 20-26, line 21.) Plaintiff argues Manbeck’s excess of 50 years of experience in the field of patent law give him an adequate basis for opining as to the conduct a lawyer in his field should adopt, and though he has had no special training in ethics, he has had generalized training (i.e. Mandatory/Minimum Continuing Legal Education) regarding ethics and avoidance of conflicts of interest. (Opp. to Motion to Strike MSA Evidence at 4.) Plaintiff also attaches a declaration from Manbeck to its Opposition, stating that despite his lack of specialized ethics training he has “certainly been well aware of ethical standards to which attorneys are held and [has] consistently complied with them throughout [his] career.” [Deck of Harry F. Manbeck ISO Opp. to Motion to Strike (“Manbeck Deck ISO Opp.”), Doc. No. 148-11, at ¶ 4.] To be admissible, “expert testimony must ... address an issue beyond the common knowledge of the average layman.” United States v. Vallejo, 237 F.3d 1008, 1019 (9th Cir.2001), amended by 246 F.3d 1150 (9th Cir.2001). Plaintiff concedes Manbeck has had no specific or special ethics training or professional experience in ethical matters, and Manbeck merely asserts he has been “aware of ethical standards.” This “awareness” hardly constitutes “knowledge, skill, experience, training, or education” in ethics beyond that of an average lawyer. Plaintiff does not cite, and the Court has not found, any binding authority stating that length of tenure in a given profession on its own, or mere “awareness” and familiarity with a disciplinary rule such as Rule 10.66 qualifies a person as an expert in the ethical matters of that profession. The Court accordingly finds Fed.R.Evid. 702 precludes Manbeck from opining as an expert on matters of attorney ethics, attorney standards of care, or conflicts of interest. *1164 However, Manbeck is qualified to opine as an expert in matters relating to patent office procedures. C. Interlocutory Summary Judgment Rendered on Liability Alone Plaintiff moves for summary adjudication of liability of its negligence and breach of fiduciary duty claims pursuant to Federal Rule of Civil Procedure 56(a). (Motion at 6.) Rule 56 requires a party moving for summary judgment to offer evidence sufficient to support a finding upon every element of the claim. Watts, 703 F.2d at 347 (9th Cir.1983) (citation omitted). Both causation and damages are necessary elements for a finding of malpractice liability as well as breach of fiduciary duty liability. Osornio v. Weingarten, 124 Cal.App.4th 304, 319, 21 Cal.Rptr.3d 246 (Cal.Ct.App.2004) (laying out the elements of a professional negligence claim); Stanley v. Richmond, 35 Cal.App.4th 1070, 1077, 41 Cal.Rptr.2d 768 (Cal.Ct.App.1995) (laying out the elements for a breach of fiduciary duty claim). However, plaintiff does not offer evidence sufficient to support a finding upon every element of its claims, because the motion only cursorily addresses the elements of causation and damages. Plaintiffs Reply explains this strategy by citing to Federal Rule of Civil Procedure 56(d)(2) (“[a]n interlocutory summary judgment may be rendered on liability alone, even if there is a genuine issue on the amount of damages,” Fed.R.Civ.P. 56(d)(2) (2008)), and by stating it seeks a court order “adjudicating liability, leaving the issues of causation and damages for trial.” (Reply at 10.) As set forth in the discussion below, plaintiff has failed to make a sufficient showing with regard to the breach element of each claim. Accordingly, the Court need not reach the question of whether plaintiff may seek summary judgment on “liability” without addressing the causation and damages elements of both claims. 8 D. Plaintiffs Motion for Summary Adjudication Re: “Negligence Liability/Missed Deadline” 1. Professional Malpractice by an Attorney: Legal Standard Plaintiff first argues it is entitled to summary judgment on its negligence claim. Plaintiff has conceded that the negligence cause of action is essentially one of legal malpractice (Memo ISO of Motion to Remand, Doc. No. 3, at 3), and the Court has treated it as such (see, e.g. Order Denying Remand, Doc. No. 14, at 7.) In its summary adjudication argument on the negligence cause of action, plaintiff lays out the elements of traditional tort negligence (“duty, breach of duty, legal cause, and resultant damage”) and then asserts that “legal malpractice claims are subject to the same legal standards as general negligence claims” (Motion at 6,) citing Osornio v. Weingarten, 124 Cal.App.4th *1165 304, 319, 21 Cal.Rptr.3d 246 (Cal.Ct.App.2004) (in which the court evaluated the scope of an attorney’s duty to non-client beneficiaries of a will). The Osomio court held there are four essential elements of a professional negligence claim: “(1) the duty of the professional to use such skill, prudence, and diligence as other members of his profession commonly possess and exercise; (2) a breach of that duty; (3) a proximate causal connection between the negligent conduct and the resulting injury; and (4) actual loss or damage resulting from the professional’s negligence. [Citations.]” Osornio v. Weingarten, 124 Cal.App.4th 304, 319, 21 Cal.Rptr.3d 246 (Cal.Ct.App.2004). See also Ambriz v. Kelegian, 146 Cal.App.4th 1519, 1531, 53 Cal.Rptr.3d 700 (Cal.Ct.App.2007); Coscia v. McKenna & Cuneo, 25 Cal.4th 1194, 1199-1200, 108 Cal.Rptr.2d 471, 25 P.3d 670 (Cal.2001) (addressing attorney negligence in criminal cases) (Opp. at 10.) The Court now addresses plaintiffs evidence as to each element. a) Element 1: Duty of Care Foley concedes that it owed Vaxiion a duty of care. (Opp. at 10.) The Court accordingly finds that the existence of a duty of care is an issue not in dispute in this case. b) Element 2: Breach of the Duty of Care i) Legal Standard In a negligence action, “[b]reach of duty is usually a fact issue for the [fact finder]; if the circumstances permit a reasonable doubt whether the defendant’s conduct violates the boundaries of ordinary care, the doubt must be resolved as an issue of fact by the [fact finder] rather than of law by the court.” Ishmael v. Millington, 241 Cal.App.2d 520, 525, 50 Cal.Rptr. 592 (Cal.Ct.App.1966). Breach of a duty of reasonable care in a professional malpractice situation is the failure of an attorney to use such skill, prudence, and diligence as other members of his profession commonly possess and exercise. Osornio v. Weingarten, 124 Cal.App.4th 304, 319, 21 Cal.Rptr.3d 246 (Cal.Ct.App.2004). In a legal malpractice action, expert testimony is required to establish the prevailing standard of skill and learning in the locality and the propriety of particular conduct by the practitioner in particular circumstances, as such standard and skill is not a matter of general knowledge. Lipscomb v. Krause, 87 Cal.App.3d 970, 975, 151 Cal.Rptr. 465 (Cal.Ct.App.1978). When a party in a professional malpractice claim moves for summary judgment and supports the motion with expert declarations as' to whether a professional’s conduct fell within the community standard of care, he is entitled to summary judgment unless the opposing party comes forward with conflicting expert evidence. Hutchinson v. United States, 838 F.2d 390, 392 (9th Cir.1988) (citing Willard v. Hagemeister, 121 Cal.App.3d 406, 412, 175 Cal.Rptr. 365, 369 (Cal.Ct.App.1981)). Expert evidence is not needed, however, when the type of conduct required by the particular circumstances is within the knowledge of laymen. Id. at 392 n. 1. ii) Failure to File On Time Plaintiff contends first Foley breached its duty of due care to Vaxiion (Motion at 7,) explaining and supporting this contention by stating “Foley & Lardner represented Vaxiion when Foley prepared and untimely filed Vaxiion’s PCT patent application on May 28, 2002.” [Transcript of January 29, 2008 Deposition of Drew Granston, Ph.D. (“Granston Depo.”), Doc. No. 94-4, Ex. C to Motion, pp. 210:11-14; 269:18-270:18.] Plaintiff solely relies on the deposition testimony and expert reports of Harry Manbeck and *1166 the deposition testimony of David Hricik, defendant’s expert witness, 9 to support this contention. (Motion at 8.) Plaintiffs expert, Mr. Manbeck, asserts: “[t]he failure to file the PCT application on or before the May 24, 2002 deadline was malpractice.” (Manbeck Report at ¶ 43.) Manbeck himself cites the PTO rules regarding general standards for competent legal representation (Id. at ¶ 40,) 10 and Kairos Scientific Inc. v. Fish & Richardson, 2006 WL 171921, 2006 Cal.App. Unpub. LEXIS 667 (Cal.Ct.App.2006), an unpublished California Court of Appeal case. In addition, plaintiff cites testimony of defendant’s expert, David Hricik, that Vaxiion and Foley and Lardner “shared” responsibility for missing the filing deadline. [Transcript of July 18, 2008 Deposition of David Hricik (“Hricik Depo.”), Doc. No. 94-44, Ex. II to Motion, p. 8.] Based upon these two experts’ statements, Vaxiion argues it is entitled to judgment on the issue of liability on the negligence claim. However, Foley asserts there are numerous disputed material facts regarding its alleged breach of duty owed to Vaxiion. In particular, Foley contends Mark Surber and in effect, Vaxiion, were the actual causes of the delay in finalizing the patent applications because of their unyielding requests for changes and modifications of the application until and including the final hour before the deadline. Foley’s expert, David Hricik, opines strict liability does not apply to missed filing deadlines under these circumstances because Foley’s ability to meet the deadline was hampered by Vaxiion. (Hricik Report at 27.) Hricik explains “a practitioner cannot file an application — or decide whether one application is better than more than one ... without client authorization, [citation omitted] [The application] process required input from the client, not unilateral action by the firm.” (Id. at 27-28.) Defendant also references this point to rebut plaintiffs claim that Hricik admitted it was Foley’s fault (because of “shared responsibility”) that the deadline was missed. The Court has already found, in Section “B” swpra, that Manbeck is not an expert *1167 qualified to render an expert opinion on attorney standards of care for purposes of this motion. Even if Manbeck’s opinion is considered, a dispute of material fact exists because Manbeck’s opinion that missing the deadline was a breach of duty regardless of the circumstances is in direct conflict with Hricik’s opinion that no such breach could have occurred because the client was at fault for the missed deadline. This disputed issue precludes summary judgment. in) Practices Surrounding Failure to Timely File Plaintiff next contends that aside from missing the deadline, Foley breached its duty of care by its conduct leading to the missed deadline. Plaintiff supports these contentions by citing to Manbeck’s reports and deposition. Manbeck’s opinions are admissible insofar as he addresses patent office procedures, because the Court has found Manbeck is qualified to opine as an expert on such matters. See Section “B” supra. First, Manbeck states Foley should have focused on filing the PCT application (and simply designated the United States as a selected country for protection) which would have secured protection domestically and abroad, as opposed to “negligently ch[oosing] only to file the United States application” when it became clear that both the United States and PCT applications could not be completed on time. [Motion at 4, 7-8; Manbeck Report at ¶¶ 44-47; Rebuttal Export Report of Harry F. Manbeck, Jr. (“Rebuttal Report”), Doc. No. 94-45, Ex. JJ to Motion at ¶¶ 5-7.] Alternatively, Foley could have added a “PCT Transmittal Letter” and a “PCT Request” to the improperly formatted request (i.e. the finished United States utility application) as opposed to attempting to reformat it at the last minute to PCT standards. According to Manbeck, under those circumstances the PTO office would have accepted the application, given it a filing date, and merely required Foley to resubmit the application on the proper paper. (Motion at 7-8; see also Manbeck Report at ¶¶ 44-47.) Manbeck asserts that a knowledgeable patent attorney would have known this procedural shortcut. (Manbeck Report at ¶ 46.) Plaintiff accordingly asserts “Foley & Lardner had all of the documentation needed to file the PCT application by 10:00 p.m. on May 24, 2002,” and cites to Granston’s deposition testimony to the effect that he “believe[d]” the noncompliant (i.e. unformatted) PCT document, if filed incorrectly, would have preserved the priority date.” (Granston Depo., pp. 291:11-296:23.) Second, Manbeck asserts there was a “lack of attorney and staff support” to accomplish the very complex PCT filing indicating “lapses in the professional representation,” (Manbeck Report at ¶ 46-47.) Specifically, Manbeck notes senior attorney Warburg was out of town on the day the filing was due, leaving his associate Granston to “fend for himself’ in a complex filing situation. Additionally he notes the fact that the computer malfunctioned during the formatting of the PCT application, and a paralegal, Sandra A’Costa, made the determination based on her knowledge that the PCT application would not be accepted if it were formatted incorrectly. Manbeck accordingly criticizes Granston’s decision to “rely wholly on a paralegal to know the law related to PCT applications,” [Motion at 8, paraphrasing July 8, 2008 Deposition of Harry F. Manbeck, Jr. (“Manbeck Depo.”), Doc. No. 94-46, Ex. KK, pp. 187:3-23, 188:3-21, 189:2-11, “23-190:23”; See also Manbeck Report ¶¶ 44-47.] Foley counters it did not breach the standard of care by filing separate U.S. patent and PCT applications as opposed to *1168 one PCT Application because “practitioners routinely, and for good reasons, file both ways ...” (Opp. at 14) [citing Mercer 11 Decl. ISO Opp. (“Mercer Decl.”) at ¶ 17.] Foley also points out Vaxiion took part in the decision to file separate applications (Granston Decl. at ¶ 15), so it could have not been a breach of the standard of care to continue to act consistently with that decision. (Opp. at 14.) In response to plaintiffs assertions Foley should have merely converted its United States application to a PCT application at the last minute, Foley argues that even if it had taken such action, it would nevertheless have been submitting an improperly formatted application after the 11:00 p.m. deadline. (Opp. at 14-15.) 12 The timeline indicates that when Granston left at 10:40 p.m. to take the completed U.S. utility application to the post office, he arrived seconds before it closed (Granston Decl. at ¶ 30,) a fact plaintiff does not dispute. Manbeck asserts it would only have taken Granston five minutes to attach a “PCT Transmittal Letter” and a “PCT Request” to the finished U.S. utility application to submit it as a PCT Application. (Manbeck Depo., pp. 190:20.) If Granston had left for the post office at 10:45 however, it would have already closed (judging by the fact he only narrowly missed filing the utility application when he left at 10:40,) in which case neither the U.S. utility application nor the PCT application would have been timely filed. By this “timeline” argument, defendant demonstrates that because plaintiff took until 10:09 p.m. to provide the materials it wished to be included in the applications, there is nothing Foley could have done to get both the PCT and U.S. utility applications to the post office on time. In response to plaintiffs arguments that Foley improperly relied on associate Granston as the primary drafter and contact person on the application, and on paralegal A’Costa for her knowledge about formatting rules for PCT applications, Foley submits: 1) Granston had extensive experience in patent filings (over 100 previous filings) (Granston Decl. at ¶¶ 1-4); 2) Vaxiion was aware of and agreed to the respective roles of Warburg and Granston (Id at ¶¶ 8, 10, Exs. G-L; Warburg Decl. at ¶¶ 9, 10, Exs. A-F; Sabbadini Depo. G., pp. 181:21-184:23; 200:25-201:11); 3) War-burg was involved in all phases of the prosecution including client meetings and review of the claims in the divisional applications [Granston Decl. at ¶¶ 18-19, Exs. G-R; Warburg Decl. at ¶¶ 10, 13-23, 25, Exs. B-K; Transcript of April, 2008 Deposition of William Gerhart (“Gerhart Depo.”), Doc. No. 116-30, Ex. I to Opp., p. 50:7-51:15) ] Warburg was available by phone on the day of the filing and even talked to Vaxiioris CEO Gerhart on that *1169 day (Warburg Decl. at ¶ 23, Ex. A; Gerhart Depo., pp. 62:9-64:1); and 5) A’Costa was a qualified patent paralegal with ample experience with PCT filings. (Granston Decl. at ¶ 29). Defendant’s expert Hricik also notes that Foley’s support personnel had “significant patent experience and training.” (Hricik Report at 8.) 13 Disputed issues of material fact exist as to plaintiffs argument that Foley’s actions leading to the missed deadline rose to the level of breach of duty. Here, as described above, even if Granston had conducted himself with the skill, prudence, and diligence of other members of his profession, according to Manbeck (i.e. converting the United States application to a PCT application at the last minute,) he still did not receive all of the materials plaintiff demanded be included in the applications until 10:09 p.m. Consequently, there is a genuine issue of fact as to whether the PCT Application would have been filed on time. Defendant has also submitted sufficient evidence to create a dispute of material fact as to whether Foley improperly relied on associate Granston as the primary drafter and contact person on the application, and on paralegal A’Costa for her knowledge about formatting rules for PCT applications. c) Elements 3 and 4: Causation and Damages The Court finds there are disputed issues of material fact as to the breach of duty element of plaintiffs legal malpractice claim and accordingly does not need to address the causation and damages elements. Plaintiffs motion for summary adjudication with respect to liability for professional negligence is DENIED. E. Plaintiff’s Motion For Summary Adjudication of Liability Re: “Constructive Fraud a.ha. Breach of Fiduciary Duty/Invalidation Attempts” Plaintiffs second claim is for “Dual Representation of Adverse Interests,” which this Court has treated as a claim of breach of fiduciary duty. (Order Denying Remand, Doc. No. 14, at 9.) 1. Breach Of Fiduciary Duty: Legal Standard Under California law breach of fiduciary duty is a “species of tort distinct from a cause of action for professional negligence.” Stanley v. Richmond, 35 Cal.App.4th 1070, 1077, 41 Cal.Rptr.2d 768 (Cal.Ct.App.1995). The elements of a cause of action for breach of fiduciary duty are: “(1) existence of a fiduciary duty; (2) breach of the fiduciary duty; and (3) damage proximately caused by the breach.” Id.; see also Benasra v. Mitchell Silberberg & Knupp LLP, 123 Cal.App.4th 1179, 1183, 20 Cal.Rptr.3d 621 (Cal.Ct.App.2004). The scope of an attorney’s duty of care to a client is based upon the California Rules of Professional Conduct, (Id. at 1086, 41 Cal.Rptr.2d 768,) specifically Rule 3-310. The relevant portions of Rule 3-310 to this case are the following: (B)(3) “A member shall not accept or continue representation of a client without providing written disclosure to the client where [t]he member has or had a *1170 legal, business, financial, professional, or personal relationship with another person or entity the member knows or reasonably should know would be affected substantially by resolution of the matter.” “(C) A member shall not, without the informed written consent of each client: (1) Accept representation of more than one client in a matter in which the interests of the clients potentially conflict; or (2) Accept or continue representation of more than one client in a matter in which the interests of the clients actually conflict; or (3) Represent a client in a matter and at the same time in a separate matter accept as a client a person or entity whose interest in the first matter is adverse to the client in the first matter.” “(E) A member shall not, without the informed written consent of the client or former client, accept employment adverse to the client or former client where, by reason of the representation of the client or former client, the member has obtained confidential information material to the employment.” Cal. Rules of Prof 1 Conduct, Rule 3-310 (2008). A violation of the Rules of Professional Conduct, in itself, does not provide the basis for civil liability. BGJ Assoc., LLC v. Wilson, 113 Cal.App.4th 1217, 1227, 7 Cal.Rptr.3d 140 (Cal.Ct.App.2003). However, “[i]t is well established that an attorney’s duties to his client are governed by the Rules of Professional Conduct, and that those rules, together with statutes and general principles relating to other fiduciary relationships, ‘help define the duty component of the fiduciary duty which an attorney owes to his client’.” American Airlines, Inc. v. Sheppard Mullin, Richter & Hampton, 96 Cal.App.4th 1017, 1032, 117 Cal.Rptr.2d 685 (Cal.Ct.App.2002) (quoting Mirabito v. Liccardo, 4 Cal.App.4th 41, 45, 5 Cal.Rptr.2d 571 (Cal.Ct.App.1992)). The court may determine the scope of an attorney’s fiduciary duty as a matter of law, but it is generally a question of fact whether the attorney has breached a fiduciary duty. Stanley, 35 Cal.App.4th at 1086-87, 41 Cal.Rptr.2d 768. Expert testimony is not required, but is admissible to establish duty and breach of duty in a claim for breach of fiduciary duty where the attorney conduct is a matter beyond common knowledge. Id. at 1087, 41 Cal.Rptr.2d 768. a) Element 1: Existence of a Fiduciary Duty Plaintiff and defendant agree defendant owed a fiduciary duty to plaintiff. (Opp. at 19.) The Court therefore finds that the existence of a fiduciary duty between Foley and Vaxiion is an issue not in dispute in this case. b) Element 2: Breach of Fiduciary Duty Plaintiff asserts Foley breached its fiduciary duty in three ways: (1) Foley simultaneously represented both Vaxiion and EnGeneIC on the “same subject matter” without disclosing such representation; (2) Foley filed “at least three patent applications on EnGenelC’s behalf that lay claim to the heart of the subject matter covered in Vaxiion’s patent applications;” and (3) Foley attempted to invalidate Vaxiion’s patent through the instant lawsuit. (Motion at 10.) i) Simultaneous Representation Plaintiff first argues Foley breached its duty to Vaxiion when the Foley Washington D.C. office accepted representation of EnGeneIC because both companies pursued patents using similar technologies. The parties do not dispute that Patent and Trademark Office Code of Professional Responsibility Section 10.66 *1171 (37 C.F.R. § 10.66 (2008) (“Section 10.66”)) 14 provides the applicable standard for determining whether Foley breached its fiduciary duty to Vaxiion when it began representing EnGenelC. (Hricik Report at 14-15, 21-23; Manbeck Depo. at 66:14-16.) Plaintiffs arguments regarding Foley’s breach of fiduciary duty by concurrent representation appear to fall into the following sub-issues: (1) lack of adequate conflict of interest check; (2) existence of differing (adverse) interests between Vaxiion and EnGenelC when Foley accepted representation of EnGenelC; and (3) whether the existence of “possible” differing interests as indicated by plaintiff’s expert rises to the level of “likely” differing interests prohibited by Section 10.66. The Court finds there are disputes of material fact regarding each sub-issue, which precludes a finding of breach as a matter of law. Sub-Issue 1: Lack of Sufficient Conflict Check Plaintiff asserts in October 2001 when Foley accepted EnGenelC as a client, Vaxiion had already, in May 2001, “filed its first broad provisional patent application related to minicell technology,” something that Foley should have discovered in a basic internal conflicts check. (Motion at 11.) Plaintiff asserts Foley never performed a conflict check, regardless of the existence of a firmwide policy for doing so. (Reply at 11.) In his report, plaintiffs expert Manbeck states based on his examination of Foley’s intake forms that “a local Washington, D.C. member of Foley & Lardner’s New Matter Committee approved the acceptance of Engenic (sic) as a client on the same date as Client Intake Forms were submitted. Thus, it seems unlikely the San Diego office had a chance to prevent the conflict from arising.” (Manbeck Report at ¶ 18.) By contrast, defendant’s expert opines that Foley’s conflict check system was more evolved than those of other patent firms at the time and “easily met the standard of care.” Defendant’s expert does not, however, address whether the conflicts check system was properly utilized in this case. (Hricik Report at 25.) Section 10.66 does not allow an attorney continue or take on employment “if the *1172 exercise of the practitioner’s independent professional judgment in behalf of a client ... would be likely to involve the practitioner in representing differing interests.” 37 C.F.R. § 10.66(a)-(b) (2008). The Court has already found Manbeck is not qualified to render an expert opinion on conflict of interest issues. Even if qualified, however, there is a dispute of material fact with regard to the conflict check procedures because neither expert can say for certain what measures Foley actually took when it accepted representation of EnGenelC. Sub-Issue 2: Existence of “Differing In terests” Plaintiff asserts because Foley had already agreed to “pursue maximum protection of Vaxiion’s minicell invention” it could not represent another company “pursuing the same minicell delivery technology protection.” (Reply at 11.) In his deposition testimony, Manbeck opined a firm cannot prosecute two patents in the broad area of “minicells,” just as it could not prosecute two patents in the area of “semiconductors.” [Transcript of July 8, 2008 Deposition of Harry F. Manbeck, Jr. (“Manbeck Depo.”), Doc. No. 116-12, Ex. “F” to Opp., pp. 142:24-144:5.] Similarly, although plaintiffs papers do not reference it, plaintiffs expert Roy Curtiss III states “[t]he EnGenelC provisional application describes nucleic acid delivery mediated by minicells produced by anomalous separation occurring at the poles of bacterial cells. As such, EnGenelC’s technology is identical to that described previously by Vaxiion in its May 24, 2001 provisional.” [Export Report of Roy Curtiss III (“Curtiss Report”), Doc. No. 94-38, Ex. CC ISO Motion at 13.] Defendant argues, by contrast, that there is a “factual dispute about whether, at the time Foley’s San Diego and D.C. attorneys represented Vaxiion and EnGenelC, they had “differing interests,” as contemplated by Section 10.66 (Opp. At 19.) Defendant’s expert Hricik states Vaxiion and EnGenelC were pursuing very different applications for the minicell technology, making them sufficiently non-adverse for Foley to represent both of them. (Hricik Report at 22-23, 36.) Hricik further argues, that many different types of patents can utilize minicell technology, explaining a search he ran on the term “minicell” and “minicells” on the U.S. Patent Office Database yielded over 300 hits and data reaching back to 1976. Accordingly, he states “just using the broad term “minicells” to determine whether a conflict exists is not effective as it will result in too many completely unrelated patent applications.” (Hricik Decl. ISO Opp. at ¶ 3.) In its Reply, plaintiff states “the Australian patent prosecution process has already proven the overlap between these inventions” (Reply at 10-11) without any additional explanation, and cites generally to an exhibit to its motion that documents Vaxiion’s patent prosecution in Australia. (Ex. F ISO Reply.) That exhibit indicates a patent application with a priority date of May 28, 2002 that was rejected by the Australian patent office on two separate occasions (Exs. “F3” and “F5” ISO Reply,) before it was ultimately accepted (Ex. “F7” ISO Reply.) Plaintiff makes no effort to tie the Australian patent process to any overlap with EnGenelC’s technology, other than making broad assertions about the existence of an overlap. Plaintiffs reference to the Australian patent prosecution is too generalized to lend much to the determination of whether Vaxiion and EnGenelC had differing interests at the time Foley began its concurrent representation of both companies. Ultimately, plaintiff has failed to demonstrate that defendant violated Section 10.66 as a matter of law. It is disputed *1173 whether EnGeneIC and Vaxiion had differing interests at the outset of Foley’s representation of EnGeneIC. The parties’ conflicting arguments indicate the following material disputed facts: (1) differing expert opinions regarding the potential for conflict of interest between two companies both pursuing patents involving minicell technology, given the disputed size of the field; (2) differing expert opinions as to whether the technologies of Vaxiion and EnGeneIC overlap; and (3) lack of a clear, detailed, and exact indication of which specific patent claims in Australia barred by EnGenelC’s technology, and a thorough explanation of why those claims were barred. Accordingly, the Court declines to find there was a breach of duty as a matter of law based on the existence of “differing interests” as contemplated by Section 10.66. Sub-Issue S: The Existence of “Likely Differing Interests” Assuming, arguendo, EnGeneIC and Vaxiion did not have differing interests when Foley accepted EnGeneIC as a client, there remains a separate issue as to whether, at the time Foley began representing EnGeneIC, the two companies were likely to develop differing interests while Foley represented them both. As indicated above, the text of Section 10.66 prohibits a practitioner from accepting employment if the exercise of her professional judgment on a client’s behalf is likely to involve the practitioner in representing different interests. Defendant’s expert Hricik opines at the time Foley accepted EnGeneIC as a client it was not “likely” to be involved in representing differing interests given its existing representation of Vaxiion (Hricik Report at 22-23.) Manbeck, plaintiffs expert, states Foley’s concurrent representation of the two companies would put the firm in a position of “possibly having to contend with Vaxiion to determine whose inventor should be awarded the patent coverage on the interfering subject matter.” (Manbeck Depo., pp. 136:16-141:19.) Defendant’s expert does not dispute that there could have been “possible” differing interests between the companies at some point in the future, but maintains “possible” is different than “likely,” which is the stricter standard required by Rule 10.66. (Hricik Report at 22-23.) Again, the Court has already found Manbeck is not qualified to testify as an expert on conflicts of interest. Even if qualified, his opinion directly conflicts with Hricik’s, creating a dispute of material fact with regard to whether EnGeneIC and Vaxiion were likely to develop differing interests while Foley represented them both. ii) Filing “Patents On EnGenelC’s Behalf’ and Attempting to “Invalidate” Vaxiion’s Patent Plaintiff next asserts Foley breached its duty to Vaxiion by attempting in 2006 and 2007 to antedate Vaxiion’s prior art reference after the PTO’s rejections of EnGenelC’s Non-Provisional U.S. Application. (Motion at 5.) Plaintiff also argues Foley’s continued representation of EnGeneIC to date violates Foley’s fiduciary duty to Vaxiion. (Plt’s Supp. Brief at 5-7.) Rule 10.66 contains no provisions regarding a law firm or practitioner’s fiduciary duty to former clients, and the parties dispute the proper standard the Court should apply to this portion of plaintiffs claim. However, the Court concludes genuine issues of material fact preclude summary judgment regardless of the legal standard the Court applies. The facts are undisputed that in 2006 and 2007 a PTO examiner rejected several *1174 claims in EnGenelC’s Non-Provisional U.S. Application in part as a result of Vaxiion’s Non-Provisional U.S. Application. [Declaration of R. Brian McCaslin in Support of Defendant Foley & Lardner’s Motion for Partial Summary Judgment on Conflicts-Related Claims (“McCaslin Decl.”), ¶¶2 and 4, Exs. A and C] In response to the examiner’s rejection, Foley on behalf of EnGeneIC submitted declarations attempting to antedate the Vaxiion prior art reference (i.e. demonstrate EnGeneIC reduced its invention to practice before Vaxiion). [McCaslin Decl., ¶¶ 3 and 5.] On July 25, 2007, the PTO withdrew its rejection of EnGenelC’s Non-Provisional Application based upon Vaxiion’s Non-Provisional U.S. Application, and instead rejected EnGenelC’s application based upon Vaxiion’s then-issued '105 Patent. [Id., ¶ 6, Ex. E.] Defendant responds it did not breach any duty to its former client Vaxiion by trying to antedate Vaxiion’s prior art reference because “as a matter of law nothing EnGeneIC (or Foley) did in the EnGeneIC office action was adverse to Vaxiion or could have resulted in an invalidation of the '105 patent.” (Opp. at 21.) 15 Defendant explains the EnGeneIC office actions were ex parte procedures between the patent examiner and Foley on EnGenelC’s behalf pursuant to 37 C.F.R. § 1.131. That regulation provides recourse for an inventor when a patent or application is rejected, allowing the party to “submit an appropriate oath or declaration to establish invention of the subject matter of the rejected claim prior to the effective date of the reference or activity on which the rejection is based.” 37 C.F.R. § 1.131 (2008). Defendant argues simply antedating a reference “has no effect on the validity of the antedated patent, or for that matter on what possible date of actual reduction to practice the owner of that patent might later establish in, for example, litigation or an interference.” (Opp. at 21, citing Hricik Report at 43-44.) In support of this argument, defendant cites to Goutzoulis v. Athale, a patent interference case in which Manbeek himself stated “in an ex parte proceeding, one may antedate a reference by a showing which is less than which would be required for a priority contest [and thus] [i]t is therefore unlikely that the showing in a Rule 131 affidavit will be of material benefit later in the interference proceeding.” Goutzoulis v. Athale, 15 U.S.P.Q.2d 1461, 1464-65 (1990). Hricik also opines Foley did not act adversely to Vaxiion by responding to the patent examiner’s attempt to antedate Vaxiion’s technology. (Hricik Report at 42.) Plaintiff states no factual or legal basis in support of its argument that a law firm’s antedating a prior client’s reference on behalf of a current client pursuant to 37 C.F.R. § 1.131 is a breach of fiduciary duty to the former client. Plaintiff makes only bald assertions that “[t]his was a course of conduct clearly designed to lead to a finding adverse to Vaxiion.” (Reply at 12.) Plaintiffs unsupported statement is insufficient in the face of Hricik’s opinion to the contrary, to establish that Foley’s actions in attempting to antedate the Vaxiion patent in 2006 and 2007 was a breach of fiduciary duty. *1175 Plaintiff also argues Foley continues to breach its duty to Vaxiion by prosecuting on EnGenelC’s behalf “four patent applications in the area of minicell delivery.” (Ht’s Supp. Brief at 5.) Plaintiff asserts the USPTO “has clearly identified the inventions encapsulated by those applications as duplicative of the Vaxiion inventions” and cites excerpts from the applications referencing teachings of Sabbadini (the '105 patent) and a Surber application. Id. Defendant responds that the documents plaintiff refers to as “patent applications” are actually three USP-TO office actions (Def.’s Reply to Plt.’s Supp. Brief at 6, referencing Pit’s Supp. Brief, Exs. B-D) and an EnGeneIC response to a separate rejection issues by a patent examiner. (Def.’s Reply to Pit’s Supp. Brief at 6, referencing Pit’s Supp. Brief, Ex. E.) Defendant explains Exhibits B and C are “restriction requirements” requesting EnGeneIC to elect a “single inventive concept” as required by PCT rules, and asserts the fact that the examiner listed features of prior art “does not mean he rendered a decision (or even considered) whether they contain the same inventions as the claims sought by EnGeneIC.” (Def.’s Reply to Pit’s Supp. Brief at 7-8.) Defendant also argues Exhibit E is an EnGeneIC office action response in which it attempted to distinguish the '105 patent from the specific claims EnGeneIC seeks, and that the response has no effect on Vaxiion’s patent. (Def.’s Reply to Pit’s Supp. Brief at 7-8.) Defendant does not comment on Exhibit D. However, plaintiff also fails to explain exactly how the patent office’s mention of Vaxiion’s '105 patent equates to an adverse action against that patent. It is apparent material facts are in dispute, precluding a finding of summary judgment. iii) Attempts to Invalidate Vaxiion’s Patent Through Instant Lawsuit Plaintiff also briefly states in its Motion that Foley breached its duty of loyalty to Vaxiion by seeking to invalidate the '105 patent “in the instant lawsuit.” (Motion at 10.) Plaintiff provides no further legal discussion of this issue. As a result, the Court finds plaintiff is not entitled to summary judgment on this portion of its breach of fiduciary duty claim. 16 c) Element 3: Damages Proximately Caused by the Breach The Court finds there are disputed issues of material fact as to the breach of fiduciary duty element of plaintiffs legal malpractice claim and accordingly needs not reach the issue of “damages proximately caused by the breach.” Plaintiffs motion for summary adjudication with respect to breach of fiduciary duty is DENIED. 2. Waiver of Conflict of Interest Vaxiion learned Foley represented EnGeneIC, at the very latest, in November of 2004. However Vaxiion never raised the issue of Foley’s continued representation of EnGeneIC until almost a year after this case was filed. As a result, Foley argues the Court should find Vaxiion waived its claim for breach of fiduciary duty. (Opp. at 24-25.) The Court rejected defendant’s identical argument in its Order Granting in Part and Denying in Part Defendant’s Motion for Summary Judgment on Conflicts-Re *1176 lated Claims (Doc. No. 169) and need not consider it again here. CONCLUSION For the reasons set forth herein, the Court DENIES plaintiffs motion for summary adjudication of liability. (Doc. No. 94.) The Court GRANTS defendant’s Motion to Strike Evidence Cited in Support of Plaintiffs Motion (Doc. No. 131,) and DENIES AS MOOT defendant’s Motion to Strike Evidence of Settlement Meeting Cited in Support of Plaintiffs Motion. (Doc. No. 146.) The Court overrules all of the parties’ evidentiary objections except those the Court specifically addresses above. IT IS SO ORDERED. Footnotes [1] Roger Sabbadini, a San Diego State University professor initially founded Vaxiion as a company called Medlyte. [Transcript of February 20, 2008 Deposition of Roger Sabbadini ("Sabbadini Depo. G”), Ex. G to Garner Decl. ISO Opp. to Motion ("Garner Decl.”), Doc. No. 116-13, pp. 9:10-13, 11:14-19, 12:4-17.] In July 2001, Sabbadini and other investors formed a new company called Mpex which purchased Medlyte’s minicell technology. Mpex changed its name to Vaxiion in 2004. (Id. 64:18-22.) For the sake of simplicity, this Order will refer to the company simply as "Vaxiion.” [2] A "minicell is a small achromosomal (i.e., without chromosomes) cell that is produced by abnormal and unequal division of a parent cell.” (Opp. at 3, n. 4.) [3] Vaxiion disputes Warburg’s level of involvement and oversight in the patent prosecution process, as is discussed further below. [4] Plaintiff states Warburg and Granston never told them about the option of filing only a single PCT application (Plaintiff’s Reply to Defendant’s Sep. Stmt, of Add! Material Facts ISO Opp., Doc. No. 141, at 41,) but cites to nothing in the record to support this allegation. [5] Plaintiff argues defendant’s motions to strike are disallowed by Fed.R.Civ.P. 12(f). This argument is misplaced because the Court has discretion to strike inadmissible evidence filed in support of a summary judgment motion. Bliesner v. Commun. Workers of Am., 464 F.3d 910, 915 (9th Cir.2006) (holding a district court did not abuse its discretion when it struck part of an affidavit supporting a motion for summary judgment). [6] Defendant also objects to the expert reports of Manbeck and plaintiff's other experts, arguing they are improperly authenticated under Fed.R.Evid. 901 and Fed.R.Civ.P. 56(e). (Memo. ISO Motion to Strike MSA Evidence at 1.) However, plaintiff submitted declarations from its experts authenticating the contested expert reports with its Opposition to defendant’s Motion to Strike MSA Evidence. *1162 (Opp. to Motion to Strike MSA Evidence, Doc. Nos. 148-3; 148-6; 148-9; 148-11.) [7] Harry F. Manbeck. Jr. is a former Assistant Secretary of Commerce and Commissioner of Patents and Trademarks of the United States, and was appointed by former President George H.W. Bush. He practiced patent law for approximately 35 years before becoming PTO Commissioner in 1990 (where he served until 1992). In his current practice he is “often asked to provide expert consulting or testimony about patent issues.” (Manbeck Report at ¶¶ 1-2.) [8] The Court is not persuaded plaintiff can seek adjudication of “liability” under Rule 56(d)(2) without making a sufficient showing for a finding on each essential element of both claims because only "genuine issues on the amount of damages” may be reserved for trial after an interlocutory summary judgment on liability. Fed. R. Civ. Proc. 56(d)(2); Van Curen v. Bank of the West (In re Hat), 2007 WL 2580688, at *7-8, 2007 Bankr.LEXIS 3055, at *22 (Bankr.E.D.Cal.2007) (holding plaintiff trustee was not entitled to interlocutory summary judgment without addressing affirmative defenses directed at the issue of respondent bank’s liability): cf. Great Am. Ins. Co. v. N. Am. Specialty Ins. Co., 542 F.Supp.2d 1203, 1211 (D.Nev.2008) (finding the defendant business partner liable for legal defense expenses it should have contributed to a past lawsuit against the partnership, even though the plaintiff, another partner, did not present evidence showing what expenses [i.e. amount of damages] it was entitled to as a matter of law). [9] Professor David Hricik is a tenured Associate Professor of Law at Mercer University School of Law, where he has taught since 2002. He teaches both ethics and patent law, among other courses. He has been the Chair of the Professionalism & Ethics Committee of the American Intellectual Property-Law Association and the Chair of the Ethics & Professionalism Committee of the Intellectual Property Law Section of the American Bar Association. He previously taught ethics at the University of Texas School of Law as well as the University of Houston Law School. Since the early 1990s he has represented clients "in legal malpractice cases, and in matters concerning disqualification and legal ethics generally, in both patent and non-patent cases and in a general advisory role.” [Export Report of Professor David Hricik ("Hricik Report”), Ex. W ISO Motion at 1-2.] Hricik has also represented clients in patent lawsuits and appeals from 1989— 2002 and has "consulted with practitioners, lawyers, and law firms across the country on patent-ethics matters ... and [has] frequently acted as a confidential ethics advisor to practitioners, lawyers, patent agent, and law firms concerning matters involving ethical issues before the United States Patent & Trademark Office (“PTO”), in patent litigation, in state court litigation, as well as in general practice.” (Id. at 2-3.) [10] § 10.76 Canon 6[¶] A practitioner should represent a client competently. [¶] 10.77 Failing to act competently. [¶] A practitioner shall not: [¶] (a) Handle a legal matter which the practitioner knows or should know that the practitioner is not competent to handle, without associating with the practitioner another practitioner who is competent to handle it. [¶] (b) Handle a legal matter without preparation adequate in the circumstances. [¶] (c) Neglect a legal matter entrusted to the practitioner. [¶] 10.78 Limiting liability to a client. [¶] A practitioner shall not attempt to exonerate himself or herself from, or limit his or her liability to, a client for his or her personal malpractice. 37 C.F.R. § 10.76 (2008). [11] Defendant retained Chris Mercer as an expert. He is a patent attorney registered in the United Kingdom, and the majority of his work involves the prosecution of applications, oppositions and appeals before the European Patent Office, but has also prosecuted applications outside of Europe, including in the United States, Canada, and Australia. He has been awarded "a Certificate as a Patent Attorney Litigator due to [his] experience in UK and foreign litigation matters,” and has also been a member of numerous patent and intellectual property professional associations. (Mercer Decl. at ¶¶ 1-15.) [12] Defendant additionally argues ”[a]s an initial matter, whether [Vaxiion] could have filed an improperly formatted PCT application is a question of law. But in any event, Vaxiion still has been able to pursue and obtain foreign patent protection, notwithstanding the missed deadline.” (Opp. to Plt.’s Sep. Stmt, of Fact # 6.) Although this may be the case, it does not mean that Foley did not breach a duty to Vaxiion by missing the deadline or by its actions the night the deadline was missed. As such, this particular defense might be relevant to the causation element' rather than the breach of duty element. [13] Foley also disputes plaintiff's contention that on May 24, 2002, only A’Costa and no attorneys worked on the PCT application. (Based on a billing statement, Ex. J to Motion.) Foley responds Granston worked on the document that would become both the United States Non-Provisional Application and the PCT Application, and the only difference between the two was the formatting, which is was A’Costa’s task. (Granston Decl. at ¶ 29; Manbeck Depo., pp. 188:3-191:16). Plaintiff does not dispute the substantive content of both applications was the same. (Pit's Reply to Def.’s Stmt, of Add! Material Facts, “L”.) [14] 37 C.F.R. § 10.66 (“Refusing to accept or continue employment if the interests of another client may impair the independent professional judgment of the practitioner”) provides: (a) A practitioner shall decline proffered employment if the exercise of the practitioner’s independent professional judgment in behalf of a client will be or is likely to be adversely affected by the acceptance of the proffered employment, or if it would be likely to involve the practitioner in representing differing interests, except to the extent permitted under paragraph (c) of this section. (b) A practitioner shall not continue multiple employment if the exercise of the practitioner’s independent professional judgment in behalf of a client will be or is likely to be adversely affected by the practitioner’s representation of another client, or if it would be likely to involve the practitioner in representing differing interests, except to the extent permitted under paragraph (c) of this section. (c) In the situations covered by paragraphs (a) and (b) of this section a practitioner may represent multiple clients if it is obvious that the practitioner can adequately represent the interest of each and if each consents to the representation after full disclosure of the possible effect of such representation on the exercise of the practitioner’s independent professional judgment on behalf of each. 37 C.F.R. § 10.66(2008). (d) If a practitioner is required to decline employment or to withdraw from employment under a Disciplinary Rule, no partner, or associate, or any other practitioner affiliated with the practitioner or the practitioner’s firm, may accept or continue such employment unless otherwise ordered by the Director or Commissioner. [15] Defendant further argues even if the antedating could have had an effect on the '105 patent’s validity, it in fact had no effect because the examiner ultimately rejected EnGenelC's antedating argument. (McCaslin Decl. at ¶ 6.) This argument is immaterial to a breach analysis, because the fact that EnGenelC’s attempt to establish an earlier date of reduction to practice failed does not negate the possibility that Foley could have breached its fiduciary duty to Vaxiion when it effected the antedating attempts for EnGeneIC. [16] The Court does find compelling defendant’s argument that any claim of breach of fiduciary duty arising from its defense in this case would be barred by the litigation privilege. Cal. Civ.Code § 47(b) (2008). However, Foley has not moved for summary judgment on this aspect of plaintiff’s claim.